Evidence-Based Analysis of a Migraine Treatment Drug Comparison Trial
- 1 October 2000
- journal article
- research article
- Published by SAGE Publications in Cephalalgia
- Vol. 20 (2_suppl) , 33-38
- https://doi.org/10.1046/j.1468-2982.2000.0200s2033.x
Abstract
Patients present with specific problems against a background of their particular situation. The applicability of a treatment to a specific case may be difficult to assess in the light of the information available on that treatment. Evidence-based medicine is a discipline developed to achieve the best informed treatment decisions in clinical situations. In this paper, we illustrate a logical approach to reaching a decision regarding which of two migraine treatments should be used in a clearly defined patient. The information evaluated is a comparative trial between sumatriptan (100 mg), rizatriptan (5 and 10 mg) and placebo. The use of the analytical tools of evidence-based medicine is demonstrated in this exercise. The example was chosen because this is an area of great current interest in the field of neurology.Keywords
This publication has 7 references indexed in Scilit:
- Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 1998
- Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in MigraineHeadache: The Journal of Head and Face Pain, 1998
- Evidence based medicine: what it is and what it isn'tBMJ, 1996
- Empirical Evidence of BiasJAMA, 1995
- Users' Guides to the Medical LiteratureJAMA, 1994
- Users' Guides to the Medical LiteratureJAMA, 1993
- Bias in Treatment Assignment in Controlled Clinical TrialsNew England Journal of Medicine, 1983